Editas Medicine receives regulatory approval to start Phase 1/2 EDIT‑401 trial in Australia
Editas Medicine announced that the Human Research Ethics Committee and Australia’s Therapeutic Goods Administration have approved the Strive Phase 1/2 trial of its gene‑editing therapy EDIT‑401 for heterozygous familial hypercholesterolemia. The company plans to begin patient dosing in 2026 and expects initial safety and tolerability data in the first quarter of 2027. Preclinical studies showed roughly a 90 % reduction in LDL‑C and related lipoproteins in non‑human primates, and the data will be presented at the American Heart Association Scientific Sessions in November 2026.
Why it matters
The approval enables Editas to move EDIT‑401 into first‑in‑human testing, creating a near‑term catalyst for safety data in Q1 2027, which could affect the company’s valuation. The company expects the trial to generate topline safety and efficacy results later in 2027, providing further insight into the therapy’s commercial potential.
Key facts
- 1Human Research Ethics Committee approval and completion of the Clinical Trial Notification process with Australia’s Therapeutic Goods Administration were obtained for the Strive trial. globenewswire.com
- 2The trial will enroll patients with heterozygous familial hypercholesterolemia in Australia and, pending review, New Zealand. globenewswire.com
- 3Editas plans to begin dosing patients in 2026. globenewswire.com
- 4Initial safety and tolerability data are expected in the first quarter of 2027. globenewswire.com
- 5Preclinical studies in non‑human primates showed an average LDL‑C reduction of approximately 90 % or greater, sustained for 10 months. sec.gov
- 6New preclinical data will be presented at the American Heart Association Scientific Sessions on November 8, 2026. globenewswire.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.